[Usefulness of 2-component human fibrin glue in stabilizing vascular sutures at risk in hemodialysis] NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Usefulness of 2-component human fibrin glue in stabilizing vascular sutures at risk in hemodialysis]

Minerva Chir. 1989 Nov 15;44(21):2241-4. Unique Identifier : AIDSLINE MED/90174441
Cavallaro G; Artuso B; Accordino A; Costa F; Bruno T; Jelasi A

Abstract: The controversies arising in recent years over the possible transmission of viruses including the hepatitis and HTLV III type in blood derivatives that have been more or less purified or screened for specific antibodies are still to be fully resolved. Though some statistical epidemiological studies seem to exclude the possibility when it comes to the use of bicomponent human fibrin glue (Tissucol) (Eder et al., 1986) it seems unreasonable totally to exclude the possibility of contamination arising from the use of this product. Certainly such contamination is only a remote possibility in haemodialysis patients who, obliged by their condition to undergo repeated intravascular injections of blood or other blood derivates, are highly unlikely to contract disease precisely due to the use of fibrin glue. For this reason, over the past three years bicomponent human fibrin glue has been used whenever necessary and has proved extremely valuable in stabilising vascular sutures at risk.
Keywords: Aged Arm/*BLOOD SUPPLY *Arteriovenous Shunt, Surgical Case Report English Abstract Female *Fibrin Tissue Adhesive *Hemodialysis Human Middle Age Risk Factors *Sutures JOURNAL ARTICLEKWDagedarm/KWDbloodsupplyKWDarteriovenousshunt,surgicalcasereportenglishabstractfemaleKWDfibrintissueadhesiveKWDhemodialysishumanmiddleageriskfactorsKWDsuturesjournalarticle
900630
M9060600

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .